When should FDG-PET be used in the modern management of lymphoma?

British Journal of Haematology

Volumn 164, Issue 3, 2014, Pages 315-328

  Barrington, Sally Fiona ^a   Mikhaeel, Nabegh George ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical trials; Hodgkin lymphoma; Imaging; Non Hodgkin lymphoma; Positron emission tomography

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE; VINDESINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RELAPSE; REMISSION; SKIN LYMPHOMA; SURVIVAL RATE; T CELL LYMPHOMA;

CLINICAL TRIALS; HODGKIN LYMPHOMA; IMAGING; NON-HODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY;

DISEASE MANAGEMENT; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 84892480590     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12601     Document Type: Article

References (104)

1. Administration of Radioactive Substances Advisory Committee (2006) Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources (2006, revised 2011). Health Protection Agency, Oxford. http://www.arsac.org.uk/notes_for_guidance/documents/ARSACNFG2006Corrected2011.pdf
2. Andre, M.P., Reman, O., Federico, M., Girinski, T., Brice, P., Brusamolino, E., Ferme, C., vander Maazen, R., Bellei, M., Sebban, C., Morschhauser, F., Lugtenburg, E., Stamatoulas, A., Fortpied, C., Meignan, M., Versari, A., Hutchings, M. & Raemaekers, J. (2012) Interim analysis of the randomized Eortc/Lysa/Fil intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts), 120, 549.
3. Avivi, I., Zilberlicht, A., Dann, E.J., Leiba, R., Faibish, T., Rowe, J.M. & Bar-Shalom, R. (2013) Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. American Journal of Hematology, 88, 400-405.
4. Barnes, J.A., LaCasce, A.S., Zukotynski, K., Israel, D., Feng, Y., Neuberg, D., Toomey, C.E., Hochberg, E.P., Canellos, G.P. & Abramson, J.S. (2011) End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Annals of Oncology, 22, 910-915.
5. Barrington, S.F. & O'Doherty, M.J. (2003) Limitations of PET for imaging lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 30, S117-S127.
6. Barrington, S.F., Qian, W., Somer, E.J., Franceschetto, A., Bagni, B., Brun, E., Almquist, H., Loft, A., Hojgaard, L., Federico, M., Gallamini, A., Smith, P., Johnson, P., Radford, J. & O'Doherty, M.J. (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 37, 1824-1833.
7. Barrington, S.F., MacKewn, J.E., Schleyer, P., Marsden, P.K., Mikhaeel, N.G., Qian, W., Mouncey, P., Patrick, P., Popova, B., Johnson, P., Radford, J. & O'Doherty, M.J. (2011) Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Annals of Oncology, 22, 739-745.
8. Berthet, L., Cochet, A., Kanoun, S., Berriolo-Riedinger, A., Humbert, O., Toubeau, M., Dygai-Cochet, I., Legouge, C., Casasnovas, O. & Brunotte, F. (2013) In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. Journal of Nuclear Medicine, 54, 1244-1250.
9. Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., Meignan, M., Malkowski, B., Hofman, M.S. & Barrington, S.F. (2013) International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. Journal of Nuclear Medicine, 54, 683-690.
10. Boellaard, R., O'Doherty, M.J., Weber, W.A., Mottaghy, F.M., Lonsdale, M.N., Stroobants, S.G., Oyen, W.J., Kotzerke, J., Hoekstra, O.S., Pruim, J., Marsden, P.K., Tatsch, K., Hoekstra, C.J., Visser, E.P., Arends, B., Verzijlbergen, F.J., Zijlstra, J.M., Comans, E.F., Lammertsma, A.A., Paans, A.M., Willemsen, A.T., Beyer, T., Bockisch, A., Schaefer-Prokop, C., Delbeke, D., Baum, R.P., Chiti, A. & Krause, B.J. (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 37, 181-200.
11. Cahu, X., Bodet-Milin, C., Brissot, E., Maisonneuve, H., Houot, R., Morineau, N., Solal-Celigny, P., Godmer, P., Gastinne, T., Moreau, P., Moreau, A., Lamy, T., Kraber-Bodere, F. & Le Gouill, S. (2011) 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 22, 705-711.
12. Campbell, J., Seymour, J.F., Matthews, J., Wolf, M., Stone, J. & Juneja, S. (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. European Journal of Haematology, 76, 473-480.
13. Casasnovas, R.O., Meignan, M., Berriolo-Riedinger, A., Bardet, S., Julian, A., Thieblemont, C., Vera, P., Bologna, S., Briere, J., Jais, J.-P., Haioun, C., Coiffier, B. & Morschhauser, F. (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood, 118, 37-43.
14. Cashen, A.F., Dehdashti, F., Luo, J., Homb, A., Siegel, B.A. & Bartlett, N.L. (2011) (18)F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. Journal of Nuclear Medicine, 52, 386-392.
15. Casulo, C., Schoder, H., Feeney, J., Lim, R., Maragulia, J., Zelenetz, A.D. & Horwitz, S. (2013) FDG-PET in the staging and prognosis of T cell lymphoma. Leukemia & Lymphoma, 54, 2163-2167.
16. Cerci, J.J., Pracchia, L.F., Linardi, C.C.G., Pitella, F.A., Delbeke, D., Izaki, M., Trindade, E., Soares Junior, J., Buccheri, V. & Meneghetti, J.C. (2010a) (18)F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. Journal of Nuclear Medicine, 51, 1337-1343.
17. Cerci, J.J., Trindade, E., Pracchia, L.F., Pitella, F.A., Linardi, C.C., Soares, J. Jr, Delbeke, D., Topfer, L.A., Buccheri, V. & Meneghetti, J.C. (2010b) Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. Journal of Clinical Oncology, 28, 1415-1421.
18. Cheah, C.Y., Hofman, M.S., Dickinson, M., Wirth, A., Westerman, D., Harrison, S.J., Burbury, K., Wolf, M., Januszewicz, H., Herbert, K., Prince, H.M., Carney, D.A., Ritchie, D.S., Hicks, R.J. & Seymour, J.F. (2013) Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. British Journal of Cancer, 109, 312-317.
19. Chen, Y.K., Yeh, C.L., Tsui, C.C., Liang, J.A., Chen, J.H. & Kao, C.H. (2011) F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clinical Nuclear Medicine, 36, 553-559.
20. Cheson, B.D. (2012) Hodgkin lymphoma: protecting the victims of our success. Journal of Clinical Oncology, 30, 4456-4457.
21. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
22. Cook, G.J., Wegner, E.A. & Fogelman, I. (2004) Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Seminars in Nuclear Medicine, 34, 122-133.
23. Devillier, R., Coso, D., Castagna, L., Brenot Rossi, I., Anastasia, A., Chiti, A., Ivanov, V., Schiano, J.M., Santoro, A., Chabannon, C., Balzarotti, M., Blaise, D. & Bouabdallah, R. (2012) Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica, 97, 1073-1079.
24. Dodero, A., Crocchiolo, R., Patriarca, F., Miceli, R., Castagna, L., Ciceri, F., Bramanti, S., Frungillo, N., Milani, R., Crippa, F., Fallanca, F., Englaro, E. & Corradini, P. (2010) Pretransplantation 18-F fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. Cancer, 116, 5001-5011.
25. Duhrsen, U., Huttmann, A., Jockel, K.H. & Muller, S. (2009) Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas - the PETAL trial. Leukemia & Lymphoma, 50, 1757-1760.
26. Dupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., Mounier, N., Gallamini, A., Feugier, P., Soubeyran, P., Colombat, P., Laurent, G., Berenger, N., Casasnovas, R.O., Vera, P., Paone, G., Xerri, L., Salles, G., Haioun, C., Meignan, M., Ghesquieres, H., Cartron, G., Seymour, J.F., Delfau-Larue, M.H., Offner, F., Soubeyran, P., Perrot, A., Brice, P., Bouabdallah, R., Sonet, A., Dupuis, J., Casasnovas, O., Catalano, J.V., Delmer, A., Jardin, F., Verney, A., Dartigues, P., Salles, G., Le Gouill, S., De Guibert, S., Planche, L., Brice, P., Dupuis, J., Cartron, G., Van Hoof, A., Casasnovas, O., Gyan, E., Tilly, H., Fruchart, C., Deconinck, E., Fitoussi, O., Gastaud, L., Delwail, V., Gabarre, J., Gressin, R., Blanc, M., Foussard, C. & Salles, G. (2012) Impact of [18F]Fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. Journal of Clinical Oncology, 30, 4317-4322.
27. El-Galaly, T., Prakash, V., Christiansen, I., Madsen, J., Johansen, P., Boegsted, M., Johnsen, H.-E. & Bukh, A. (2011) Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leukemia & Lymphoma, 52, 597-603.
28. El-Galaly, T.C., d'Amore, F., Mylam, K.J., de Nully Brown, P., Bogsted, M., Bukh, A., Specht, L., Loft, A., Iyer, V., Hjorthaug, K., Nielsen, A.L., Christiansen, I., Madsen, C., Johnsen, H.E. & Hutchings, M. (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. Journal of Clinical Oncology, 30, 4508-4514.
29. El-Galaly, T., Mylam, K., Brown, P., Rossing, M., Gang, A., Haglund, A., Arboe, B., Clausen, M., Jensen, P., Pedersen, M., Bukh, A., Amdi Jensen, B., Poulsen, C., D'Amore, F. & Hutchings, M. (2013) Patient reported symptoms are still the single most important factor for detecting lymphoma relapse. Hematological Oncology, 31(S1), 172, Abstract 225.
30. Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J.A., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A., Kim, S., Alavi, A. & Schuster, S.J. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, 3875-3876.
31. Elstrom, R., Leonard, J.P., Coleman, M. & Brown, R.K. (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Annals of Oncology, 19, 1770-1773.
32. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Kral, Z., Fuchs, M., Hallek, M., Kanz, L., Dohner, H., Dorken, B., Engel, N., Topp, M., Klutmann, S., Amthauer, H., Bockisch, A., Kluge, R., Kratochwil, C., Schober, O., Greil, R., Andreesen, R., Kneba, M., Pfreundschuh, M., Stein, H., Eich, H.T., Muller, R.P., Dietlein, M., Borchmann, P. & Diehl, V. (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, 379, 1791-1799.
33. Feeney, J., Horwitz, S., Gonen, M. & Schoder, H. (2010) Characterization of T-cell lymphomas by FDG PET/CT. American Journal of Roentgenology, 195, 333-340.
34. Fuertes, S., Setoain, X., Lopez-Guillermo, A., Carrasco, J.L., Rodriguez, S., Rovira, J. & Pons, F. (2013) Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 40, 496-504.
35. Furth, C., Amthauer, H., Hautzel, H., Steffen, I.G., Ruf, J., Schiefer, J., Schoenberger, S., Henze, G., Grandt, R., Hundsdoerfer, P., Dietlein, M. & Kobe, C. (2011) Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma-results for dedicated assessment criteria in a blinded dual-centre read. Annals of Oncology, 22, 1198-1203.
36. Gallamini, A. (2010) Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica, 95, 1046-1048.
37. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2- F-18 Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746-3752.
38. Ghesquieres, H., Berger, F., Felman, P., Callet-Bauchu, E., Bryon, P.A., Traverse-Glehen, A., Thieblemont, C., Baseggio, L., Michallet, A.S., Coiffier, B. & Salles, G. (2006) Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. Journal of Clinical Oncology, 24, 5234-5241.
39. Girinsky, T., Ghalibafian, M., Bonniaud, G., Bayla, A., Magne, N., Ferreira, I. & Lumbroso, J. (2007) Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 85, 178-186.
40. Goldschmidt, N., Or, O., Klein, M., Savitsky, B. & Paltiel, O. (2011) The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Annals of Hematology, 90, 165-171.
41. Gollub, M.J., Hong, R., Sarasohn, D.M. & Akhurst, T. (2007) Limitations of CT during PET/CT. Journal of Nuclear Medicine, 48, 1583-1591.
42. Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F. & Meignan, M. (2005) F-18 fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood, 106, 1376-1381.
43. Hutchings, M. (2011) Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients? [Comment]. Leukemia & Lymphoma, 52, 1615-1616.
44. Hutchings, M., Mikhaeel, N.G., Fields, P.A., Nunan, T. & Timothy, A.R. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals of Oncology, 16, 1160-1168.
45. Hutchings, M., Loft, A., Hansen, M., Pedersen, L.M., Berthelsen, A.K., Keiding, S., D'Amore, F., Boesen, A.M., Roemer, L. & Specht, L. (2006a) Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica-the Hematology Journal, 91, 482-489.
46. Hutchings, M., Loft, A., Hansen, M., Pedersen, L.M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.M., Berthelsen, A.K. & Specht, L. (2006b) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, 52-59.
47. International Commission on Radiological Protection (2007) 2007 Recommendations of the International Commission on Radiological Protection. Annals of the International Commission on Radiological Protection, 37, 71-77.
48. Itti, E., Lin, C., Dupuis, J., Paone, G., Capacchione, D., Rahmouni, A., Haioun, C. & Meignan, M. (2009) Prognostic value of interim (18)F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. Journal of Nuclear Medicine, 50, 527-533.
49. Itti, E., Meignan, M., Berriolo-Riedinger, A., Biggi, A., Cashen, A.F., Vera, P., Tilly, H., Siegel, B.A., Gallamini, A., Casasnovas, R.O. & Haioun, C. (2013) An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax. European Journal of Nuclear Medicine and Molecular Imaging, 40, 1312-1320.
50. Janikova, A., Bolcak, K., Pavlik, T., Mayer, J. & Kral, Z. (2008) Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clinical Lymphoma & Myeloma, 8, 287-293.
51. Juweid, M.E., Wiseman, G.A., Vose, J.M., Ritchie, J.M., Menda, Y., Wooldridge, J.E., Mottaghy, F.M., Rohren, E.M., Blumstein, N.M., Stolpen, A., Link, B.K., Reske, S.N., Graham, M.M. & Cheson, B.D. (2005) Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. Journal of Clinical Oncology, 23, 4652-4661.
52. Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R.J., Weber, W.A., Reske, S.N., Schwaiger, M., Schwartz, L.H., Zijlstra, J.M., Siegel, B.A., Cheson, B.D. & Imaging Subcommittee of International Harmonization Project in, L. (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology, 25, 571-578.
53. Karam, M., Novak, L., Cyriac, J., Ali, A., Nazeer, T. & Nugent, F. (2006) Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer, 107, 175-183.
54. Khan, A.B., Barrington, S.F., Mikhaeel, N.G., Hunt, A.A., Cameron, L., Morris, T. & Carr, R. (2013) PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood, 122, 61-67.
55. Lambert, J.R., Bomanji, J.B., Peggs, K.S., Thomson, K.J., Chakraverty, R.K., Fielding, A.K., Kottaridis, P.D., Roughton, M., Morris, E.C., Goldstone, A.H., Linch, D.C., Ell, P.J. & Mackinnon, S. (2010) Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood, 115, 2763-2768.
56. Larcos, G. & Maisey, M.N. (1996) FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nuclear Medicine Communications, 17, 197-198.
57. Le Roux, P.Y., Gastinne, T., Le Gouill, S., Nowak, E., Bodet-Milin, C., Querellou, S., Mahe, B., Dubruille, V., Blin, N., Salaun, P.Y. & Bodere-Kraeber, F. (2011) Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. European Journal of Nuclear Medicine and Molecular Imaging, 38, 1064-1071.
58. Lee, A.I., Zuckerman, D.S., Van den Abbeele, A.D., Aquino, S.L., Crowley, D., Toomey, C., Lacasce, A.S., Feng, Y., Neuberg, D.S. & Hochberg, E.P. (2010) Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer, 116, 3835-3842.
59. Lin, C., Itti, E., Haioun, C., Petegnief, Y., Luciani, A., Dupuis, J., Paone, G., Talbot, J.N., Rahmouni, A. & Meignan, M. (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. Journal of Nuclear Medicine, 48, 1626-1632.
60. Luminari, S., Biasoli, I., Arcaini, L., Versari, A., Rusconi, C., Merli, F., Spina, M., Ferreri, A.J., Zinzani, P.L., Gallamini, A., Mastronardi, S., Boccomini, C., Gaidano, G., D'Arco, A.M., Di Raimondo, F., Carella, A.M., Santoro, A., Musto, P. & Federico, M. (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Annals of Oncology, 24, 2108-2112.
61. Markova, J., Kahraman, D., Kobe, C., Skopalova, M., Mocikova, H., Klaskova, K., Dedeckova, K., Eich, H.T., Boll, B., Dietlein, M. & Kozak, T. (2012) Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia & Lymphoma, 53, 64-70.
62. Meignan, M., Itti, E., Bardet, S., Lumbroso, J., Edeline, V., Olivier, P., Borght, T.V., Reman, O., Karcher, G., Mundler, O., Mounier, N., Ricci, R., Federico, M., Raemaekers, J. & Andre, M. (2009a) Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. Journal of Clinical Oncology, 27, 2739-2741.
63. Meignan, M., Gallamini, A. & Haioun, C. (2009b) Report on the first international workshop on interim-PET-scan in lymphoma. Leukemia & Lymphoma, 50, 1257-1260.
64. Micallef, I.N., Maurer, M.J., Wiseman, G.A., Nikcevich, D.A., Kurtin, P.J., Cannon, M.W., Perez, D.G., Soori, G.S., Link, B.K., Habermann, T.M. & Witzig, T.E. (2011) Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood, 118, 4053-4061.
65. Mikhaeel, N.G., Hutchings, M., Fields, P.A., O'Doherty, M.J. & Timothy, A.R. (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Annals of Oncology, 16, 1514-1523.
66. Mocikova, H., Pytlik, R., Markova, J., Steinerova, K., Kral, Z., Belada, D., Trnkova, M., Trneny, M., Koza, V., Mayer, J., Zak, P. & Kozak, T. (2011) Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leukemia & Lymphoma, 52, 1668-1674.
67. Moskowitz, C.H., Matasar, M.J., Zelenetz, A.D., Nimer, S.D., Gerecitano, J., Hamlin, P., Horwitz, S., Moskowitz, A.J., Noy, A., Palomba, L., Perales, M.A., Portlock, C., Straus, D., Maragulia, J.C., Schoder, H. & Yahalom, J. (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood, 119, 1665-1670.
68. Naumann, R., Beuthien-Baumann, B., Reiss, A., Schulze, J., Hanel, A., Bredow, J., Kuhnel, G., Kropp, J., Hanel, M., Laniado, M., Kotzerke, J. & Ehninger, G. (2004) Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. British Journal of Cancer, 90, 620-625.
69. O'Doherty, M.J., Barrington, S.F., Campbell, M., Lowe, J. & Bradbeer, C.S. (1997) PET scanning and the human immunodeficiency virus-positive patient. Journal of Nuclear Medicine, 38, 1575-1583.
70. Otero, H.J., Jagannathan, J.P., Prevedello, L.M., Johnston, C.J., Ramaiya, N.H., Van den Abbeele, A.D. & DiPiro, P.J. (2009) CT and PET/CT findings of T-cell lymphoma. American Journal of Roentgenology, 193, 349-358.
71. Palmer, J., Goggins, T., Broadwater, G., Chao, N., Horwitz, M., Beaven, A., Sullivan, K., Coleman, R.E. & Rizzieri, D. (2011) Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplantation, 46, 847-851.
72. Paone, G., Itti, E., Haioun, C., Gaulard, P., Dupuis, J., Lin, C. & Meignan, M. (2009) Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. European Journal of Nuclear Medicine and Molecular Imaging, 36, 745-750.
73. Partridge, S., Timothy, A., O'Doherty, M.J., Hain, S.F., Rankin, S. & Mikhaeel, G. (2000) 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 11, 1273-1279.
74. Pelosi, E., Pregno, P., Penna, D., Deandreis, D., Chiappella, A., Limerutti, G., Vitolo, U., Mancini, M., Bisi, G. & Gallo, E. (2008) Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. La Radiologia Medica, 113, 578-590.
75. Pinilla, I., Gomez-Leon, N., Del Campo-Del Val, L., Hernandez-Maraver, D., Rodriguez-Vigil, B., Jover-Diaz, R. & Coya, J. (2011) Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 55, 567-575.
76. Pregno, P., Chiappella, A., Bello, M., Botto, B., Ferrero, S., Franceschetti, S., Giunta, F., Ladetto, M., Limerutti, G., Menga, M., Nicolosi, M., Priolo, G., Puccini, B., Rigacci, L., Salvi, F., Vaggelli, L., Passera, R., Bisi, G. & Vitolo, U. (2012) Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood, 119, 2066-2073.
77. Quarles van Ufford, H.M., van Tinteren, H., Stroobants, S.G., Riphagen, I.I. & Hoekstra, O.S. (2010) Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis. Journal of Nuclear Medicine, 51, 1507-1516.
78. Raanani, P., Shasha, Y., Perry, C., Metser, U., Naparstek, E., Apter, S., Nagler, A., Polliack, A., Ben-Bassat, I. & Even-Sapir, E. (2006) Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Annals of Oncology, 17, 117-122.
79. Radford, J., Barrington, S., Counsell, N., Pettengell, R., Johnson, P., Wimperis, J., Coltart, S., Culligan, D., Lister, A., Bessell, E., Kruger, A., Popova, B., Hancock, B., Hoskin, P., Illidge, T. & O'Doherty, M. (2012) Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial. Blood (ASH Annual Meeting Abstracts), 120, 547.
80. Safar, V., Dupuis, J., Itti, E., Jardin, F., Fruchart, C., Bardet, S., Vera, P., Copie-Bergman, C., Rahmouni, A., Tilly, H., Meignan, M. & Haioun, C. (2012) Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. Journal of Clinical Oncology, 30, 184-190.
81. Schaefer, N.G., Hany, T.F., Taverna, C., Seifert, B., Stumpe, K.D., von Schulthess, G.K. & Goerres, G.W. (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology, 232, 823-829.
82. Schoder, H., Noy, A., Gonen, M., Weng, L., Green, D., Erdi, Y.E., Larson, S.M. & Yeung, H.W. (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 4643-4651.
83. Sehn, L.H., Scott, D.W., Chhanabhai, M., Berry, B., Ruskova, A., Berkahn, L., Connors, J.M. & Gascoyne, R.D. (2011) Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. Journal of Clinical Oncology, 29, 1452-1457.
84. Shrimpton, P., Hillier, M., Lewis, M.A. & Dunn, M. (2005) NRPB - W67 Doses from Computed Tomography (CT) Examinations in the UK - 2003 Review. National Radiological Protection Board, Oxford. ISBN: 0-85951-556-7.
85. Smeltzer, J.P., Cashen, A.F., Zhang, Q., Homb, A., Dehdashti, F., Abboud, C.N., Dipersio, J.F., Stockerl-Goldstein, K.E., Uy, G.L., Vij, R., Westervelt, P., Bartlett, N.L. & Fehniger, T.A. (2011) Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation, 17, 1646-1652.
86. Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L. & Verhoef, G. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? Journal of Clinical Oncology, 19, 414-419.
87. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L. & Verhoef, G. (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Annals of Oncology, 13, 1356-1363.
88. Specht, L., Yahalom, J., Illidge, T., Berthelsen, A.K., Constine, L.S., Eich, H.T., Girinsky, T., Hoppe, R.T., Mauch, P., Mikhaeel, N.G. & Ng, A. (2013) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology, Biology, Physics, doi: 10.1016/j.ijrobp.2013.05.005.
89. Strobel, K., Schaefer, N.G., Renner, C., Veit-Haibach, P., Husarik, D., Koma, A.Y. & Hany, T.F. (2007) Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 18, 658-664.
90. Sucak, G.T., Ozkurt, Z.N., Suyani, E., Yasar, D.G., Akdemir, O.U., Aki, Z., Yegin, Z.A., Yagci, M. & Kapucu, O.L. (2011) Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Annals of Hematology, 90, 1329-1336.
91. Terasawa, T., Dahabreh, I.J. & Nihashi, T. (2010) Fluorine-18-Fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist, 15, 750-759.
92. Thomson, K.J., Kayani, I., Ardeshna, K., Morris, E.C., Hough, R., Virchis, A., Goldstone, A.H., Linch, D.C. & Peggs, K.S. (2013) A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin lymphoma. Leukemia, 27, 1419-1422.
93. Trotman, J., Fournier, M., Lamy, T., Seymour, J.F., Sonet, A., Janikova, A., Shpilberg, O., Gyan, E., Tilly, H., Estell, J., Forsyth, C., Decaudin, D., Fabiani, B., Gabarre, J., Salles, B., Van den Neste, E., Canioni, D., Garin, E., Fulham, M., Vander Borght, T. & Salles, G. (2011) Positron Emission Tomography-Computed Tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. Journal of Clinical Oncology, 29, 3194-3200.
94. Tsukamoto, N., Kojima, M., Hasegawa, M., Oriuchi, N., Matsushima, T., Yokohama, A., Saitoh, T., Handa, H., Endo, K. & Murakami, H. (2007) The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer, 110, 652-659.
95. Watanabe, R., Tomita, N., Takeuchi, K., Sakata, S., Tateishi, U., Tanaka, M., Fujita, H., Inayama, Y. & Ishigatsubo, Y. (2010) SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leukemia & Lymphoma, 51, 279-283.
96. Weiler-Sagie, M., Bushelev, O., Epelbaum, R., Dann, E.J., Haim, N., Avivi, I., Ben-Barak, A., Ben-Arie, Y., Bar-Shalom, R. & Israel, O. (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. Journal of Nuclear Medicine, 51, 25-30.
97. Wirth, A., Foo, M., Seymour, J.F., Macmanus, M.P. & Hicks, R.J. (2008) Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. International Journal of Radiation Oncology, Biology, Physics, 71, 213-219.
98. Yang, D.-H., Min, J.-J., Song, H.-C., Jeong, Y.Y., Chung, W.-K., Bae, S.-Y., Ahn, J.-S., Kim, Y.-K., Bom, H.-S., Chung, I.-J., Kim, H.-J. & Lee, J.-J. (2011) Prognostic significance of interim (18)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. European Journal of Cancer, 47, 1312-1318.
99. Yang, D.H., Ahn, J.S., Byun, B.H., Min, J.J., Kweon, S.S., Chae, Y.S., Sohn, S.K., Lee, S.W., Kim, H.W., Jung, S.H., Kim, Y.K., Kim, H.J., Bom, H.S. & Lee, J.J. (2013) Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Annals of Hematology, 92, 471-479.
100. Yoo, C., Lee, D.H., Kim, J.E., Jo, J., Yoon, D.H., Sohn, B.S., Kim, S.-W., Lee, J.-S. & Suh, C. (2011) Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Annals of Hematology, 90, 797-802.
101. Zinzani, P.L. (2011) PET in T-cell lymphoma. Current Hematologic Malignancy Reports, 6, 241-244.
102. Zinzani, P.L., Tani, M., Trisolini, R., Fanti, S., Stefoni, V., Alifano, M., Castellucci, P., Musuraca, G., Dalpiaz, G., Alinari, L., Marchi, E., Fina, M., Pellegrini, C., Farsad, M., Cancellieri, A., Busca, A., Canini, R., Pileri, S., Baccarani, M. & Boaron, M. (2007) Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica, 92, 771-777.
103. Zinzani, P.L., Gandolfi, L., Broccoli, A., Argnani, L., Fanti, S., Pellegrini, C., Stefoni, V., Derenzini, E., Quirini, F. & Baccarani, M. (2011) Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer, 117, 1010-1018.
104. Zinzani, P.L., Rigacci, L., Stefoni, V., Broccoli, A., Puccini, B., Castagnoli, A., Vaggelli, L., Zanoni, L., Argnani, L., Baccarani, M. & Fanti, S. (2012) Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. European Journal of Nuclear Medicine and Molecular Imaging, 39, 4-12.